GENinCode (LSE:GENI) Accounts Payable : £1.38 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is GENinCode Accounts Payable?

GENinCode's Accounts Payable for the quarter that ended in Jun. 2024 was £1.38 Mil.

GENinCode's quarterly Accounts Payable increased from Jun. 2023 (£0.91 Mil) to Dec. 2023 (£1.19 Mil) and increased from Dec. 2023 (£1.19 Mil) to Jun. 2024 (£1.38 Mil).

GENinCode's annual Accounts Payable increased from Dec. 2021 (£0.35 Mil) to Dec. 2022 (£1.42 Mil) but then declined from Dec. 2022 (£1.42 Mil) to Dec. 2023 (£1.19 Mil).

GENinCode Accounts Payable Historical Data

The historical data trend for GENinCode's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GENinCode Accounts Payable Chart

GENinCode Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

0.39

0.19

0.35

1.42

1.19

GENinCode Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Accounts Payable	Get a 7-Day Free Trial				0.80	1.42	0.91	1.19	1.38

GENinCode Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

GENinCode Accounts Payable Related Terms

Thank you for viewing the detailed overview of GENinCode's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

GENinCode Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » GENinCode PLC (LSE:GENI) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Oxford Science Park, John Eccles House, Robert Robertson Avenue, Oxford, GBR, OX4 4GP

Website

https://www.genincode.com

GENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension, and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom.